Back
Compare AU
Compare TECH vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X Morningstar Global Technology ETF (TECH) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
TECH | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 207 | 68 |
Median incremental investment | $729.82 | $665.63 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,579.09 | $1,929.75 |
Average age group | > 35 | > 35 |
Key Summary
TECH | CURE | |
|---|---|---|
Strategy | The Global X Morningstar Global Technology ETF (TECH: ASX) seeks to track the performance of the Morningstar Developed Markets Technology Moat Focus Index before considering any fees, expenses, or taxes. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | Marvell Technology Inc (4.49 %) Fortinet Inc (4.33 %) Advanced Micro Devices Inc (4.31 %) | Madrigal Pharmaceuticals Inc (1.44 %) TG Therapeutics Inc (1.38 %) Insmed Inc (1.35 %) |
Top 3 industries | Information Technology (79.96 %) Financials (10.64 %) Industrials (9.70 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | United States (62.10 %) Netherlands (9.59 %) Germany (6.87 %) | United States (96.62 %) United Kingdom of Great Britain and Northern Ireland (1.35 %) Switzerland (1.13 %) |
Management fee | 0.45 % | 0.45 % |
Key Summary
TECH | CURE | |
|---|---|---|
Issuer | Global X | Global X |
Tracking index | Morningstar Developed Markets Technology Moat Focus Index - USD | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.45 % | 0.45 % |
Price | $83.11 | $62.25 |
Size | $263.129 million | $38.988 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 6.51 % | 5.08 % |
Market | ASX | ASX |
First listed date | 11/04/2017 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
TECH | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 207 | 68 |
Median incremental investment | $729.82 | $665.63 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,579.09 | $1,929.75 |
Average age group | > 35 | > 35 |
Pros and Cons
TECH | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
TECH | CURE |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |